6 completed, 3 terminated, 1 withdrawn. 10 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Completed 6, Terminated 3, Withdrawn 1 |
Follow bococizumab: new trials by email Literature Review of bococizumab trials Research Report on bococizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy And Safety Of Bococizumab For Lipid Lowering In Asian Hypercholesterolemia Subjects Bococizumab, Placebo - Primary Hyperlipidemia or Mixed Dyslipidemia | Phase 3 | Withdrawn | Pfizer | 2016-10-31 | 2017-12-02 | |
| Bococizumab HIV Evaluation (B-HIVE) Study Bococizumab, Placebo - Dyslipidemia, Cardiovascular Disease | Phase 3 | Terminated | University of California, San Francisco | 11 | 2016-08-01 | 2019-06-19 |
| Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia Bococizumab 150mg, Bococizumab 75mg, Bococizumab 150mg placebo - Hyperlipidemia | Phase 3 | Completed | Pfizer | 299 | 2015-06-01 | 2017-12-19 |
| Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events Bococizumab (PF-04950615; RN316), Placebo - Hyperlipidemia | Phase 3 | Completed | Pfizer | 746 | 2014-10-28 | 2018-07-31 |
| Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins Bococizumab (PF-04950615;RN316), Atorvastatin, Placebo for Bococizumab (PF-04950615;RN316) - Hyperlipidemia | Phase 3 | Completed | Pfizer | 184 | 2014-06-01 | 2017-12-14 |
| Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events Bococizumab (PF-04950615; RN316), Placebo - Hyperlipidemia | Phase 3 | Completed | Pfizer | 2139 | 2013-10-29 | 2018-07-31 |
| The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects bococizumab (PF-04950615), Placebo - Cardiovascular Disease | Phase 3 | Terminated | Pfizer | 10564 | 2013-10-29 | 2019-05-01 |
| The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects bococizumab (PF-04950615), Placebo - Cardiovascular Disease | Phase 3 | Terminated | Pfizer | 16784 | 2013-10-29 | 2018-07-11 |
| A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia Bococizumab (PF-04950615;RN316), Placebo - Heterozygous Familial Hypercholesterolemia | Phase 3 | Completed | Pfizer | 370 | 2013-10-23 | 2017-06-26 |
| Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events Bococizumab (PF-04950615;RN316), Placebo - Hyperlipidemia | Phase 3 | Completed | Pfizer | 711 | 2013-10-01 | 2017-05-17 |
Hyperlipidemias (7) · Cardiovascular Diseases (3) · Myocardial Infarction (2) · Stroke (2) · Dyslipidemias (1)
Pfizer (9) · University of California, San Francisco (1)
United States (9) · Canada (7) · Poland (5) · United Kingdom (5) · Czechia (4) · Finland (4) · Italy (4) · Netherlands (4) · South Korea (4) · Spain (4) · Australia (3) · Colombia (3) · France (3) · Germany (3) · Hungary (3)
PMID 28304227, PMID 29685591, PMID 35277540, PMID 37994400, PMID 37658997, PMID 28304242, PMID 29716940, PMID 31529318
2014 (1)